Valuation: PTC Therapeutics, Inc.

Capitalization 4.04B 3.49B 3.29B 2.97B 5.5B 346B 6.2B 38.19B 14.91B 159B 15.16B 14.84B 581B P/E ratio 2025 *
9.52x
P/E ratio 2026 * -21.2x
Enterprise value 2.49B 2.15B 2.03B 1.83B 3.39B 213B 3.82B 23.53B 9.19B 97.97B 9.34B 9.14B 358B EV / Sales 2025 *
1.59x
EV / Sales 2026 * 3x
Free-Float
97.66%
Yield 2025 *
-
Yield 2026 * -
More valuation ratios * Estimated data
Dynamic Chart
1 day+0.31%
1 week-1.45%
Current month+5.07%
1 month+10.80%
3 months-4.91%
6 months+7.64%
Current year+12.94%
More quotes
1 week 50.33
Extreme 50.33
52.93
1 month 44.04
Extreme 44.04
52.98
Current year 35.95
Extreme 35.95
58.38
1 year 28.72
Extreme 28.72
58.38
3 years 17.53
Extreme 17.53
59.84
5 years 17.53
Extreme 17.53
70.82
10 years 4.03
Extreme 4.03
70.82
More quotes
Manager TitleAgeSince
Chief Executive Officer 53 2023-03-21
Director of Finance/CFO 40 2023-07-12
Chief Tech/Sci/R&D Officer 57 2021-12-31
Director TitleAgeSince
Chairman 73 2004-10-31
Director/Board Member 79 1998-03-30
Director/Board Member 64 2005-11-30
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
+0.31%-1.45%+35.33%+90.22% 4.03B
+0.42%+6.05%-6.37%+173.40% 726B
+0.90%+1.95%+7.74%-9.21% 374B
+0.48%+8.92%-47.13%+32.18% 353B
+0.48%+2.64%+15.85%+34.37% 338B
+1.00%+2.02%+12.83%-13.17% 264B
+1.10%+2.11%+4.24%+16.86% 232B
+1.14%+2.45%-10.88%+11.97% 229B
+1.87%+5.41%-37.16%-6.15% 202B
+1.88%+3.55%-1.26%+23.87% 157B
Average +0.81%+2.34%-2.68%+35.43% 287.88B
Weighted average by Cap. +0.59%+3.36%-6.49%+52.61%
See all sector performances

Financials

2025 *2026 *
Net sales 1.56B 1.35B 1.27B 1.15B 2.13B 134B 2.4B 14.76B 5.76B 61.45B 5.86B 5.74B 224B 878M 759M 714M 646M 1.2B 75.21B 1.35B 8.3B 3.24B 34.55B 3.29B 3.23B 126B
Net income 643M 556M 523M 474M 876M 55.09B 987M 6.08B 2.37B 25.31B 2.41B 2.36B 92.46B -202M -175M -165M -149M -276M -17.34B -310M -1.91B -747M -7.96B -759M -743M -29.09B
Net Debt -1.55B -1.34B -1.26B -1.14B -2.11B -133B -2.38B -14.65B -5.72B -61.01B -5.82B -5.69B -223B -1.41B -1.21B -1.14B -1.03B -1.91B -120B -2.16B -13.28B -5.19B -55.3B -5.27B -5.16B -202B
More financial data * Estimated data
Logo PTC Therapeutics, Inc.
PTC Therapeutics, Inc. is a global biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. The Company has a diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. It has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD) a rare, life-threatening disorder. Its Upstaza, a gene therapy for the treatment of Aromatic L-Amino Decarboxylase (AADC) deficiency, a rare central nervous system (CNS) disorder. Its Tegsedi and Waylivra are for the treatment of rare diseases. Its Evrysdi, a treatment for spinal muscular atrophy (SMA).
Employees
939
More about the company
Date Price Change Volume
25-06-12 50.98 $ +0.31% 597,604
25-06-11 50.82 $ -1.78% 608,839
25-06-10 51.74 $ +0.10% 827,719
25-06-09 51.69 $ -0.84% 967,121
25-06-06 52.13 $ +0.77% 936,061

Delayed Quote Nasdaq, June 12, 2025 at 04:00 pm EDT

More quotes
Trading Rating
Investor Rating
ESG MSCI
BB
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
50.98USD
Average target price
61.67USD
Spread / Average Target
+20.96%
Consensus

Quarterly revenue - Rate of surprise